G G Graham


Affiliation: University of New South Wales
Country: Australia


  1. Graham G, Punt J, Arora M, Day R, Doogue M, Duong J, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81-98 pubmed publisher
    ..We suggest that the mean plasma concentrations of metformin over a dosage interval be maintained below 2.5 mg/L in order to minimize the development of this adverse effect. ..
  2. Graham G, Day R, Graudins A, Mohamudally A. FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?. Inflammopharmacology. 2010;18:47-55 pubmed publisher
    ..Adoption of these two recommendations may lead to the increased use of NSAIDs with the potential of increasing incidence of NSAIDs-related adverse reactions. ..
  3. Kannangara D, Ramasamy S, Indraratna P, Stocker S, Graham G, Jones G, et al. Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. Arthritis Res Ther. 2012;14:R189 pubmed publisher
    ..Spot-FCU determinations may provide useful correlates in studies investigating molecular mechanisms underpinning the observed range of efficiencies of the kidneys in clearing urate from the blood. ACTRN12611000743965. ..
  4. Graham G, Davies M, Day R, Mohamudally A, Scott K. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology. 2013;21:201-32 pubmed publisher
    ..There is considerable debate about the hepatotoxicity of therapeutic doses of paracetamol. Much of the toxicity may result from overuse of combinations of paracetamol with opioids which are widely used, particularly in USA. ..